In this issue:
Tarlatamab for previously treated SCLC
Osimertinib ± chemotherapy in EGFR-mutated advanced NSCLC
First-line selpercatinib vs. chemotherapy (±pembrolizumab) in RET fusion+ NSCLC
Adding pembrolizumab to chemotherapy in advanced pleural mesothelioma
Adding berzosertib to topotecan for relapsed SCLC
Patritumab deruxtecan for EGFR-mutated NSCLC after EGFR-TKI and platinum
Durvalumab after radiation for chemoradiotherapy-ineligible stage III NSCLC
Bintrafusp alfa vs. pembrolizumab in treatment-naive, PDL1-high advanced NSCLC
Brigatinib vs. alectinib in ALK-positive NSCLC after progression on crizotinib
First-line osimertinib for advanced EGFR-mutated NSCLC in the elderly
Please login below to download this issue (PDF)